{"id":"clemastine","rwe":[{"pmid":"41780166","year":"2026","title":"Oligodendrocyte-specificfusdepletion preserves CA1 single-unit fidelity and stabilizes network dynamics during chronic recording.","finding":"","journal":"Journal of neural engineering","studyType":"Clinical Study"},{"pmid":"41758934","year":"2026","title":"Immune-adaptive pathogen variation reveals targetable mediators of gram-positive bacterial killing in macrophages.","finding":"","journal":"Science advances","studyType":"Clinical Study"},{"pmid":"41755774","year":"2026","title":"Clemastine Restores Myelination Protein Expression in S16 Schwann Cells by Enhancing AMPK Activation and Reducing H(2)O(2)-Induced Oxidative Stress.","finding":"","journal":"Biomolecules & therapeutics","studyType":"Clinical Study"},{"pmid":"41719338","year":"2026","title":"Clemastine fumarate promotes myelin repair in a nonhuman primate model of demyelination characterized by absent spontaneous remyelination.","finding":"","journal":"Proceedings of the National Academy of Sciences of the United States of America","studyType":"Clinical Study"},{"pmid":"41690435","year":"2026","title":"Myelin damage in major depressive disorder: Insights from neuroimaging, molecular mechanisms, and therapeutic perspectives.","finding":"","journal":"Neuroscience and biobehavioral reviews","studyType":"Clinical Study"}],"_fda":{"id":"1c00b77a-2510-443b-9ecc-dc6f953b50b0","set_id":"5c99e7af-86a5-4c17-82d5-2d4119e4fe72","openfda":{"unii":["19259EGQ3D"],"route":["ORAL"],"rxcui":["857430"],"spl_id":["1c00b77a-2510-443b-9ecc-dc6f953b50b0"],"brand_name":["Clemastine Fumarate"],"spl_set_id":["5c99e7af-86a5-4c17-82d5-2d4119e4fe72"],"package_ndc":["64950-324-12"],"product_ndc":["64950-324"],"generic_name":["CLEMASTINE FUMARATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["CLEMASTINE FUMARATE"],"manufacturer_name":["Genus Lifesciences"],"application_number":["ANDA073399"],"is_original_packager":[true]},"version":"1","warnings":["WARNINGS Antihistamines should be used with considerable caution in patients with: narrow angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, and bladder neck obstruction. Use with CNS Depressants Clemastine has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.). Use in Activities Requiring Mental Alertness Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc. Use in the Elderly (approximately 60 years or older) Antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients."],"pregnancy":["Pregnancy Teratogenic Effects Pregnancy Category B Oral reproduction studies performed with clemastine fumarate in rats and rabbits at doses up to 312 and 188 times the adult human doses respectively, have revealed no evidence of teratogenic effects. There are no adequate and well-controlled studies of clemastine fumarate in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed."],"overdosage":["OVERDOSAGE Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. In children, stimulation predominates initially in a syndrome which may include excitement, hallucinations, ataxia, incoordination, muscle twitching, athetosis, hyperthermia, cyanosis convulsions, tremors, and hyperreflexia followed by postictal depression and cardio-respiratory arrest. Convulsions in children may be preceded by mild depression. Dry mouth, fixed dilated pupils, flushing of the face, and fever are common. In adults, CNS depression, ranging from drowsiness to coma, is more common. The convulsant dose of antihistamines lies near the lethal dose. Convulsions indicate a poor prognosis. In both children and adults, coma and cardiovascular collapse may occur. Deaths are reported especially in infants and children. There is no specific therapy for acute overdosage with antihistamines. The latent period from ingestion to appearance of toxic effects is characteristically short (1/2-2 hours). General symptomatic and supportive measures should be instituted promptly and maintained for as long as necessary. Since overdoses of other classes of drugs (i.e. tricyclic antidepressants) may also present anticholinergic symptomatology, appropriate toxicological analysis should be performed as soon as possible to identify the causative agent. In the conscious patient, vomiting should be induced even though it may have occurred spontaneously. If vomiting cannot be induced, gastric lavage is indicated. Adequate precautions must be taken to protect against aspiration, especially in infants and children. Charcoal slurry or other suitable agents should be instilled into the stomach after vomiting or lavage. Saline cathartics or milk of magnesia may be of additional benefit. In the unconscious patient, the airway should be secured with a cuffed endotracheal tube before attempting to evacuate the gastric contents. Intensive supportive and nursing care is indicated, as for any comatose patient. If breathing is significantly impaired, maintenance of an adequate airway and mechanical support of respiration is the most effective means of providing adequate oxygenation. Hypotension is an early sign of impending cardiovascular collapse and should be treated vigorously. Although general supportive measures are important, specific treatment with intravenous infusion of a vasopressor titrated to maintain adequate blood pressure may be necessary. Do not use with CNS stimulants. Convulsions should be controlled by careful administration of diazepam or a short-acting barbiturate, repeated as necessary. Physostigmine may also be considered for use in controlling centrally mediated convulsions. Ice packs and cooling sponge baths, not alcohol, can aid in reducing the fever commonly seen in children. A more detailed review of antihistamine toxicology and overdose management is available in Gosselin, R.E., et. al., \"Clinical Toxicology of Commercial Products.\""],"description":["DESCRIPTION Each 5 mL (teaspoonful) of Clemastine Fumarate Syrup for oral administration contains clemastine 0.5 mg (present as clemastine fumarate 0.67 mg). Other ingredients: Alcohol 5.5%, Flavors, Maleic Acid, Methylparaben, Propylene Glycol, Propylparaben, Purified Water, Saccharin Sodium, Sodium Hydroxide, and Sorbitol. Clemastine fumarate belongs to the benzhydryl ether group of antihistaminic compounds. The chemical name is (+)-(2R)-2-[2-[[(R)-p-Chloro-α-methyl-α-phenylbenzyl]-oxy]ethyl]-1-methylpyrrolidine fumarate and has the following structural formula: C 21 H 26 ClNO∙C 4 H 4 O 4 M.W. 459.97 Clemastine fumarate occurs as a colorless to faintly yellow, odorless, crystalline powder. Clemastine Fumarate Syrup has an approximate pH of 6.2. Chemical Structure"],"precautions":["PRECAUTIONS General Clemastine fumarate should be used with caution in patients with: history of bronchial asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease, and hypertension. Information for Patients Patients taking antihistamines should receive the following information and instructions: Antihistamines are prescribed to reduce allergic symptoms. Patients should be questioned regarding a history of glaucoma, peptic ulcer, urinary retention, or pregnancy before starting antihistamine therapy. Patients should be told not to take alcohol, sleeping pills, sedatives, or tranquilizers while taking antihistamines. Antihistamines may cause drowsiness, dizziness, dry mouth, blurred vision, weakness, nausea, headache, or nervousness in some patients. Patients should avoid driving a car or working with hazardous machinery until they assess the effects of this medicine. Patients should be told to store this medicine in a tightly closed container in a dry, cool place away from heat or direct sunlight and out of the reach of children. Drug Interactions Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol. Patients receiving antihistamines should be advised against the concurrent use of other CNS depressant drugs. Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines. Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis and Mutagenesis In a 2-year oral study in the rat at a dose of 84 mg/kg (about 500 times the adult human dose) and an 85-week oral study in the mouse at 206 mg/kg (about 1300 times the adult human dose), clemastine fumarate showed no evidence of carcinogenesis. No mutagenic studies have been conducted with clemastine fumarate. Impairment of Fertility Oral doses of clemastine fumarate in the rat produced a decrease in mating ability of the male at 312 times the adult human dose. This effect was not found at 156 times the adult human dose. Pregnancy Teratogenic Effects Pregnancy Category B Oral reproduction studies performed with clemastine fumarate in rats and rabbits at doses up to 312 and 188 times the adult human doses respectively, have revealed no evidence of teratogenic effects. There are no adequate and well-controlled studies of clemastine fumarate in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed. Nursing Mothers Although quantitative determinations of antihistaminic drugs in breast milk have not been reported, qualitative tests have documented the excretion of diphenhydramine, pyrilamine, and tripelennamine in human milk. Because of the potential for adverse reactions in nursing infants from antihistamines, a decision should be made whether to discontinue nursing or to discontinue the drug. Pediatric Use The safety and efficacy of Clemastine Fumarate Syrup has been confirmed in the pediatric population (age 6 years through 12). Safety and dose tolerance studies have confirmed pediatric patients 6 through 11 years tolerated dosage ranges of 0.75 to 2.25 mg clemastine. In pediatric patients particularly, antihistamines in overdosage may produce hallucinations, convulsions and death. Symptoms of antihistamine toxicity in pediatric patients may include fixed dilated pupils, flushed face, dry mouth, fever, excitation, hallucinations, ataxia, incoordination, athetosis, tonic- lonic convulsions, and postictal depression (see OVERDOSAGE )."],"how_supplied":["HOW SUPPLIED Clemastine Fumarate Syrup: clemastine 0.5 mg/5 mL (present as clemastine fumarate 0.67 mg/5 mL). A clear, colorless liquid with a citrus flavor (passion fruit), in 120 mL bottle. 120 mL bottle (NDC 64950-324-12) Store at controlled room temperature, between 20° and 25°C (68° and 77°F) (see USP)."],"pediatric_use":["Pediatric Use The safety and efficacy of Clemastine Fumarate Syrup has been confirmed in the pediatric population (age 6 years through 12). Safety and dose tolerance studies have confirmed pediatric patients 6 through 11 years tolerated dosage ranges of 0.75 to 2.25 mg clemastine. In pediatric patients particularly, antihistamines in overdosage may produce hallucinations, convulsions and death. Symptoms of antihistamine toxicity in pediatric patients may include fixed dilated pupils, flushed face, dry mouth, fever, excitation, hallucinations, ataxia, incoordination, athetosis, tonic- lonic convulsions, and postictal depression (see OVERDOSAGE )."],"effective_time":"20241125","nursing_mothers":["Nursing Mothers Although quantitative determinations of antihistaminic drugs in breast milk have not been reported, qualitative tests have documented the excretion of diphenhydramine, pyrilamine, and tripelennamine in human milk. Because of the potential for adverse reactions in nursing infants from antihistamines, a decision should be made whether to discontinue nursing or to discontinue the drug."],"pharmacokinetics":["Pharmacokinetics Antihistamines are well-absorbed following oral administration. Chlorpheniramine maleate, clemastine fumarate, and diphenhydramine hydrochloride achieve peak blood levels within 2-5 hours following oral administration. The absorption of antihistamines is often partially delayed by the use of controlled release dosage forms. In these instances, plasma concentrations from identical doses of the immediate and controlled release dosage forms will not be similar. Tissue distribution of the antihistamines in humans has not been established. Antihistamines appear to be metabolized in the liver chiefly via mono- and didemethylation and glucuronide conjugation. Antihistamine metabolites and small amounts of unchanged drug are excreted in the urine. Small amounts of the drugs may also be excreted in breast milk. In normal human subjects who received histamine injections over a 24-hour period, the antihistaminic activity of clemastine reached a peak at 5-7 hours, persisted for 10-12 hours and, in some cases, for as long as 24 hours. Pharmacokinetic studies in man utilizing 3H and 14C labeled compound demonstrates that: clemastine is rapidly absorbed from the gastrointestinal tract, peak plasma concentrations are attained in 2-4 hours, and urinary excretion is the major mode of elimination."],"adverse_reactions":["ADVERSE REACTIONS The most frequent adverse reactions are italicized: Nervous System Sedation , sleepiness , dizziness , disturbed coordination , fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis, convulsions. Gastrointestinal System Epigastric distress , anorexia, nausea, vomiting, diarrhea, constipation. Respiratory System Thickening of bronchial secretions , tightness of chest and wheezing, nasal stuffiness. Cardiovascular System Hypotension, headache, palpitations, tachycardia, extrasystoles. Hematologic System Hemolytic anemia, thrombocytopenia, agranulocytosis. Genitourinary System Urinary frequency, difficult urination, urinary retention, early menses. General Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of mouth, nose and throat. To report SUSPECTED ADVERSE REACTIONS, contact Allucent at 1-866-511-6754 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["CONTRAINDICATIONS Antihistamines are contraindicated in patients hypersensitive to the drug or to other antihistamines of similar chemical structure (see PRECAUTIONS- Drug Interactions ). Antihistamines should not be used in newborn or premature infants . Because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers (see PRECAUTIONS-Nursing Mothers )."],"description_table":["<table width=\"100%\" styleCode=\"Noautorules\"><col align=\"center\" valign=\"top\" width=\"50%\"/><col align=\"center\" valign=\"top\" width=\"50%\"/><tbody><tr><td colspan=\"2\"><renderMultiMedia referencedObject=\"MM1\"/></td></tr><tr><td>C<sub>21</sub>H<sub>26</sub>ClNO&#x2219;C<sub>4</sub>H<sub>4</sub>O<sub>4</sub></td><td>M.W. 459.97</td></tr></tbody></table>"],"drug_interactions":["Drug Interactions Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol. Patients receiving antihistamines should be advised against the concurrent use of other CNS depressant drugs. Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines."],"general_precautions":["General Clemastine fumarate should be used with caution in patients with: history of bronchial asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease, and hypertension."],"teratogenic_effects":["Teratogenic Effects Pregnancy Category B Oral reproduction studies performed with clemastine fumarate in rats and rabbits at doses up to 312 and 188 times the adult human doses respectively, have revealed no evidence of teratogenic effects. There are no adequate and well-controlled studies of clemastine fumarate in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed."],"storage_and_handling":["Store at controlled room temperature, between 20° and 25°C (68° and 77°F) (see USP)."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Clemastine fumarate is an antihistamine with anticholinergic (drying) and sedative side effects. Antihistamines competitively antagonize various physiological effects of histamine including increased capillary permeability and dilatation, the formation of edema, the \"flare\" and \"itch\" response, and gastrointestinal and respiratory smooth muscle constriction. Within the vascular tree, H1-receptor antagonists inhibit both the vasoconstrictor and vasodilator effects of histamine. Depending on the dose, H1-receptor antagonists can produce CNS stimulation or depression. Most antihistamines exhibit central and/or peripheral anticholinergic activity. Antihistamines act by competitively blocking H1-receptor sites. Antihistamines do not pharmacologically antagonize or chemically inactivate histamine, nor do they prevent the release of histamine. Pharmacokinetics Antihistamines are well-absorbed following oral administration. Chlorpheniramine maleate, clemastine fumarate, and diphenhydramine hydrochloride achieve peak blood levels within 2-5 hours following oral administration. The absorption of antihistamines is often partially delayed by the use of controlled release dosage forms. In these instances, plasma concentrations from identical doses of the immediate and controlled release dosage forms will not be similar. Tissue distribution of the antihistamines in humans has not been established. Antihistamines appear to be metabolized in the liver chiefly via mono- and didemethylation and glucuronide conjugation. Antihistamine metabolites and small amounts of unchanged drug are excreted in the urine. Small amounts of the drugs may also be excreted in breast milk. In normal human subjects who received histamine injections over a 24-hour period, the antihistaminic activity of clemastine reached a peak at 5-7 hours, persisted for 10-12 hours and, in some cases, for as long as 24 hours. Pharmacokinetic studies in man utilizing 3H and 14C labeled compound demonstrates that: clemastine is rapidly absorbed from the gastrointestinal tract, peak plasma concentrations are attained in 2-4 hours, and urinary excretion is the major mode of elimination."],"indications_and_usage":["INDICATIONS AND USAGE Clemastine Fumarate Syrup is indicated for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus and lacrimation. Clemastine Fumarate Syrup is indicated for use in pediatric populations (age 6 years through 12) and adults (see DOSAGE AND ADMINISTRATION ). It should be noted that clemastine is indicated for the relief of mild uncomplicated allergic skin manifestations of urticaria and angioedema at the 2 mg dosage level only."],"information_for_patients":["Information for Patients Patients taking antihistamines should receive the following information and instructions: Antihistamines are prescribed to reduce allergic symptoms. Patients should be questioned regarding a history of glaucoma, peptic ulcer, urinary retention, or pregnancy before starting antihistamine therapy. Patients should be told not to take alcohol, sleeping pills, sedatives, or tranquilizers while taking antihistamines. Antihistamines may cause drowsiness, dizziness, dry mouth, blurred vision, weakness, nausea, headache, or nervousness in some patients. Patients should avoid driving a car or working with hazardous machinery until they assess the effects of this medicine. Patients should be told to store this medicine in a tightly closed container in a dry, cool place away from heat or direct sunlight and out of the reach of children."],"spl_unclassified_section":["Rx only","Distributed By: Genus Lifesciences Inc. Allentown, PA 18102 Rev. 09/24"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND RESPONSE OF THE PATIENT. Pediatric Children aged 6 to 12 years For Symptoms of Allergic Rhinitis The starting dose is 1 teaspoonful (0.5 mg clemastine) twice daily. Since single doses of up to 2.25 mg clemastine were well tolerated by this age group, dosage may be increased as required, but not to exceed 6 teaspoonfuls daily (3 mg clemastine). For Urticaria and Angioedema The starting dose is 2 teaspoonfuls (1 mg clemastine) twice daily, not to exceed 6 teaspoonfuls daily (3 mg clemastine). Adults and Children 12 Years and Over For Symptoms of Allergic Rhinitis The starting dose is 2 teaspoonfuls (1 mg clemastine) twice daily. Dosage may be increased as required, but not to exceed 12 teaspoonfuls daily (6 mg clemastine). For Urticaria and Angioedema The starting dose is 4 teaspoonfuls (2 mg clemastine) twice daily, not to exceed 12 teaspoonfuls daily (6 mg clemastine)."],"spl_product_data_elements":["Clemastine Fumarate Clemastine Fumarate Clemastine Fumarate Clemastine ALCOHOL MALEIC ACID METHYLPARABEN PROPYLENE GLYCOL PROPYLPARABEN SACCHARIN SODIUM SORBITOL WATER SODIUM HYDROXIDE PASSION FRUIT"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 120 mL Bottle Label NDC 64950-324-12 Clemastine Fumarate Syrup 0.5 mg/5 mL* Each 5 mL (teaspoonful) contains: Clemastine 0.5 mg* Alcohol 5.5% *(present as clemastine fumarate 0.67 mg) Rx only 120 mL Genus Lifesciences Inc. PRINCIPAL DISPLAY PANEL - 120 mL Bottle Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis and Mutagenesis In a 2-year oral study in the rat at a dose of 84 mg/kg (about 500 times the adult human dose) and an 85-week oral study in the mouse at 206 mg/kg (about 1300 times the adult human dose), clemastine fumarate showed no evidence of carcinogenesis. No mutagenic studies have been conducted with clemastine fumarate. Impairment of Fertility Oral doses of clemastine fumarate in the rat produced a decrease in mating ability of the male at 312 times the adult human dose. This effect was not found at 156 times the adult human dose."]},"tags":[{"label":"clemastine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"D(3) dopamine receptor","category":"target"},{"label":"DRD3","category":"gene"},{"label":"HRH1","category":"gene"},{"label":"CHRM4","category":"gene"},{"label":"D04AA14","category":"atc"},{"label":"Oral","category":"route"},{"label":"ORAL","category":"route"},{"label":"Syrup","category":"form"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Allergic conjunctivitis","category":"indication"},{"label":"Allergic rhinitis","category":"indication"},{"label":"Anaphylaxis Adjunct","category":"indication"},{"label":"Dermatographic urticaria","category":"indication"},{"label":"Itching of skin","category":"indication"},{"label":"Nasal congestion","category":"indication"},{"label":"Approved 1970s","category":"decade"},{"label":"Anti-Allergic Agents","category":"pharmacology"},{"label":"Antipruritics","category":"pharmacology"},{"label":"Dermatologic Agents","category":"pharmacology"},{"label":"Histamine Agents","category":"pharmacology"},{"label":"Histamine Antagonists","category":"pharmacology"},{"label":"Histamine H1 Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"106 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"102 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"82 reports"},{"date":"","signal":"ERYTHEMA","source":"FDA FAERS","actionTaken":"78 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"76 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"74 reports"},{"date":"","signal":"CONSTIPATION","source":"FDA FAERS","actionTaken":"67 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"67 reports"},{"date":"","signal":"SEPSIS","source":"FDA FAERS","actionTaken":"62 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"61 reports"}],"commonSideEffects":[{"effect":"Urticaria","drugRate":"reported","severity":"unknown"},{"effect":"drug rash","drugRate":"reported","severity":"unknown"},{"effect":"anaphylactic shock","drugRate":"reported","severity":"unknown"},{"effect":"photosensitivity","drugRate":"reported","severity":"unknown"},{"effect":"excessive perspiration","drugRate":"reported","severity":"unknown"},{"effect":"chills","drugRate":"reported","severity":"unknown"},{"effect":"dryness of the mouth","drugRate":"reported","severity":"unknown"},{"effect":"dryness of the nose","drugRate":"reported","severity":"unknown"},{"effect":"dryness of the throat","drugRate":"reported","severity":"unknown"},{"effect":"Hypotension","drugRate":"reported","severity":"unknown"},{"effect":"headache","drugRate":"reported","severity":"unknown"},{"effect":"palpitations","drugRate":"reported","severity":"unknown"},{"effect":"tachycardia","drugRate":"reported","severity":"unknown"},{"effect":"extrasystoles","drugRate":"reported","severity":"unknown"},{"effect":"Hemolytic anemia","drugRate":"reported","severity":"unknown"},{"effect":"thrombocytopenia","drugRate":"reported","severity":"unknown"},{"effect":"agranulocytosis","drugRate":"reported","severity":"unknown"},{"effect":"Sedation","drugRate":"reported","severity":"unknown"},{"effect":"sleepiness","drugRate":"reported","severity":"unknown"},{"effect":"dizziness","drugRate":"reported","severity":"unknown"},{"effect":"disturbed coordination","drugRate":"reported","severity":"unknown"},{"effect":"fatigue","drugRate":"reported","severity":"unknown"},{"effect":"confusion","drugRate":"reported","severity":"unknown"},{"effect":"restlessness","drugRate":"reported","severity":"unknown"},{"effect":"excitation","drugRate":"reported","severity":"unknown"},{"effect":"nervousness","drugRate":"reported","severity":"unknown"},{"effect":"tremor","drugRate":"reported","severity":"unknown"},{"effect":"irritability","drugRate":"reported","severity":"unknown"},{"effect":"insomnia","drugRate":"reported","severity":"unknown"},{"effect":"euphoria","drugRate":"reported","severity":"unknown"}],"contraindications":["Angle-closure glaucoma","Benign prostatic hyperplasia","Bladder outflow obstruction","Chronic idiopathic constipation","Hypertensive disorder","Hyperthyroidism","Ocular hypertension","Peptic ulcer","Retention of urine"],"specialPopulations":{"Pregnancy":"Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed.","Paediatric use":"The safety and efficacy of Clemastine Fumarate Syrup has been confirmed in the pediatric population (age years through 12). Safety and dose tolerance studies have confirmed children through 11 years tolerated dosage ranges of 0.75 to 2.25 mg clemastine. In infants and children particularly, antihistamines in overdosage may produce hallucinations, convulsions, and death."}},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CLEMASTINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:26:03.261196+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Clemastine","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:26:10.795750+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:26:09.324136+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:26:02.381985+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CLEMASTINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:26:09.740124+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:25:58.366525+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:25:58.366553+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:26:11.372645+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Histamine H1 receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:26:10.795686+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200795/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:26:10.446440+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA073399","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:25:58.366557+00:00"}},"allNames":"tavist","offLabel":[],"synonyms":["clemastine","meclastine","clemastine fumarate"],"timeline":[{"date":"1977-02-25","type":"positive","source":"DrugCentral","milestone":"FDA approval"},{"date":"1985-06-28","type":"positive","source":"FDA Orange Book","milestone":"Tavist approved — EQ 0.5MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"1992-04-21","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 3 manufacturers approved"},{"date":"1992-08-21","type":"positive","source":"FDA Orange Book","milestone":"Tavist-1 approved — 1.34MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"}],"approvals":[{"date":"1977-02-25","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Tavist","ecosystem":[{"indication":"Allergic conjunctivitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alcaftadine","slug":"alcaftadine","company":"Allergan"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":null},{"indication":"Allergic rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"astemizole","slug":"astemizole","company":""}],"globalPrevalence":null},{"indication":"Anaphylaxis Adjunct","otherDrugs":[{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"azatadine","slug":"azatadine","company":""},{"name":"diphenylpyraline","slug":"diphenylpyraline","company":"Glaxosmithkline"},{"name":"pheniramine","slug":"pheniramine","company":"Alcon"}],"globalPrevalence":null},{"indication":"Dermatographic urticaria","otherDrugs":[{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"azatadine","slug":"azatadine","company":""},{"name":"brompheniramine","slug":"brompheniramine","company":""}],"globalPrevalence":68000000},{"indication":"Itching of skin","otherDrugs":[{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"allantoin","slug":"allantoin","company":""},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":null},{"indication":"Nasal congestion","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":null},{"indication":"Nasal discharge","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":30000000},{"indication":"Sneezing","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"astemizole","slug":"astemizole","company":""}],"globalPrevalence":null}],"mechanism":{"target":"D(3) dopamine receptor","novelty":"Follow-on","targets":[{"gene":"DRD3","source":"DrugCentral","target":"D(3) dopamine receptor","protein":"D(3) dopamine receptor"},{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor"},{"gene":"CHRM4","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M4","protein":"Muscarinic acetylcholine receptor M4"},{"gene":"CHRM5","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M5","protein":"Muscarinic acetylcholine receptor M5"},{"gene":"CHRM3","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M3","protein":"Muscarinic acetylcholine receptor M3"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"KCNH2","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2"},{"gene":"ADRA2C","source":"DrugCentral","target":"Alpha-2C adrenergic receptor","protein":"Alpha-2C adrenergic receptor"},{"gene":"SIGMAR1","source":"DrugCentral","target":"Sigma non-opioid intracellular receptor 1","protein":"Sigma non-opioid intracellular receptor 1"},{"gene":"ADRA1D","source":"DrugCentral","target":"Alpha-1D adrenergic receptor","protein":"Alpha-1D adrenergic receptor"}],"modality":"Small Molecule","drugClass":"clemastine","explanation":"","oneSentence":"","technicalDetail":"Clemastine is a selective D(3) dopamine receptor antagonist that competes with histamine for binding sites on the receptor, thereby inhibiting the histamine-mediated response and alleviating allergic symptoms."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Clemastine","title":"Clemastine","extract":"Clemastine, also known as meclastin, is a first-generation H1 histamine antagonist (antihistamine) with anticholinergic properties (drying) and sedative side effects. Like all first-generation antihistamines, it is sedating.","wiki_society_and_culture":"==Society and culture==\nClemastine is an OTC drug, and is available under many names and dosage forms worldwide. Most common brand name is Tavegyl."},"commercial":{"launchDate":"1977","_launchSource":"DrugCentral (FDA 1977-02-25, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/671","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CLEMASTINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CLEMASTINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Clemastine","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:06:23.846829","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:26:15.564507+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"mepyramine","drugSlug":"mepyramine","fdaApproval":"1973-08-07","relationship":"same-class"},{"drugName":"tripelennamine","drugSlug":"tripelennamine","fdaApproval":"1948-02-19","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"promethazine","drugSlug":"promethazine","fdaApproval":"1951-03-29","genericCount":48,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"pheniramine","drugSlug":"pheniramine","fdaApproval":"1994-06-08","relationship":"same-class"},{"drugName":"diphenhydramine","drugSlug":"diphenhydramine","fdaApproval":"1946-03-04","genericCount":56,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"clemastine","indications":{"approved":[{"name":"Allergic conjunctivitis","source":"DrugCentral","snomedId":473460002,"regulator":"FDA","eligibility":"Adults and children 6 years and older"},{"name":"Allergic rhinitis","source":"DrugCentral","snomedId":61582004,"regulator":"FDA","eligibility":"Adults and children 6 years and older"},{"name":"Anaphylaxis Adjunct","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults and children 6 years and older"},{"name":"Dermatographic urticaria","source":"DrugCentral","snomedId":7632005,"regulator":"FDA","eligibility":"Adults and children 6 years and older","usPrevalence":null,"globalPrevalence":68000000,"prevalenceMethod":"curated","prevalenceSource":"Allergy, 2020 (PMID:31494963)"},{"name":"Itching of skin","source":"DrugCentral","snomedId":418363000,"regulator":"FDA","eligibility":"Adults and children 6 years and older"},{"name":"Nasal congestion","source":"DrugCentral","snomedId":68235000,"regulator":"FDA","eligibility":"Adults and children 6 years and older"},{"name":"Nasal discharge","source":"DrugCentral","snomedId":64531003,"regulator":"FDA","eligibility":"Adults and children 6 years and older","usPrevalence":null,"globalPrevalence":30000000,"prevalenceMethod":"curated","prevalenceSource":"Influenza Other Respir Viruses, 2023 (PMID:36824394)"},{"name":"Sneezing","source":"DrugCentral","snomedId":76067001,"regulator":"FDA","eligibility":"Adults and children 6 years and older"},{"name":"Urticaria","source":"DrugCentral","snomedId":126485001,"regulator":"FDA","eligibility":"Adults and children 6 years and older","usPrevalence":null,"globalPrevalence":68000000,"prevalenceMethod":"curated","prevalenceSource":"Allergy, 2020 (PMID:31494963)"},{"name":"Vasomotor rhinitis","source":"DrugCentral","snomedId":8229003,"regulator":"FDA","eligibility":"Adults and children 6 years and older"}],"offLabel":[],"pipeline":[]},"currentOwner":"Novartis","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"mepyramine","brandName":"mepyramine","genericName":"mepyramine","approvalYear":"1973","relationship":"same-class"},{"drugId":"tripelennamine","brandName":"tripelennamine","genericName":"tripelennamine","approvalYear":"1948","relationship":"same-class"},{"drugId":"promethazine","brandName":"promethazine","genericName":"promethazine","approvalYear":"1951","relationship":"same-class"},{"drugId":"pheniramine","brandName":"pheniramine","genericName":"pheniramine","approvalYear":"1994","relationship":"same-class"},{"drugId":"diphenhydramine","brandName":"diphenhydramine","genericName":"diphenhydramine","approvalYear":"1946","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03109288","phase":"PHASE1,PHASE2","title":"Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-08-11","conditions":["Multiple Sclerosis"],"enrollment":250,"completionDate":"2029-01-01"},{"nctId":"NCT06315699","phase":"PHASE2","title":"Clemastine Fumarate in the Treatment of Neurodevelopmental Delays in Williams Syndrome","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-03-20","conditions":["Williams Syndrome","Child","Neurodevelopmental Delay"],"enrollment":28,"completionDate":"2025-12-30"},{"nctId":"NCT05359653","phase":"PHASE1,PHASE2","title":"Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2023-08-01","conditions":["Multiple Sclerosis (MS)","Multiple Sclerosis, Relapsing-Remitting","Multiple Sclerosis, Primary Progressive","Multiple Sclerosis, Chronic Progressive","Multiple Sclerosis Relapse","Multiple Sclerosis Brain Lesion","Multiple Sclerosis Benign"],"enrollment":74,"completionDate":"2026-06-01"},{"nctId":"NCT06065670","phase":"PHASE1,PHASE2","title":"Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-09-15","conditions":["Demyelinating Diseases","Demyelination; Corpus Callosum","Multiple Sclerosis Brain Lesion","Multiple Sclerosis Acute and Progressive","Clinically Isolated Syndrome, CNS Demyelinating"],"enrollment":44,"completionDate":"2028-10-30"},{"nctId":"NCT02521311","phase":"PHASE2","title":"Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2017-02-28","conditions":["Optic Neuritis"],"enrollment":90,"completionDate":"2028-08"},{"nctId":"NCT06087757","phase":"PHASE2","title":"Clemastine Treatment in Individuals With Williams Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sheba Medical Center","startDate":"2024-04-01","conditions":["Williams Syndrome"],"enrollment":30,"completionDate":"2026-07"},{"nctId":"NCT07304024","phase":"PHASE1,PHASE2","title":"A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2025-12-15","conditions":["Central Auditory Processing Disorder","Hearing Impaired (Partially)","Hearing","Hearing Abnormality","Hearing Disability","Hearing Disorder","Hearing Disorders","Hearing Impairment, Sensorineural","Hearing Handicap","Hearing Impaired","Hearing Impairment","Hearing Loss","Central Auditory Disease","Noise Exposure","Noise Induced Hearing Loss","Noise-Induced Hearing Loss","Sound Perception","Myelin Degeneration","Myelinopathy","Myelin Integrity","Remyelination","Hidden Hearing Loss","Cocktail Party Skill","Cocktail Party Syndrome","CAPD","Age Problem"],"enrollment":344,"completionDate":"2028-07"},{"nctId":"NCT05131828","phase":"PHASE2","title":"CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2022-03-08","conditions":["Multiple Sclerosis"],"enrollment":70,"completionDate":"2025-09-26"},{"nctId":"NCT02040298","phase":"PHASE2","title":"Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2014-01","conditions":["Multiple Sclerosis, Relapsing-Remitting"],"enrollment":50,"completionDate":"2016-04"},{"nctId":"NCT06591091","phase":"PHASE2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-09","conditions":["Depression"],"enrollment":80,"completionDate":"2026-03"},{"nctId":"NCT05338450","phase":"PHASE3","title":"Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis","status":"RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2022-08-30","conditions":["Multiple Sclerosis","Internuclear Ophthalmoplegia"],"enrollment":80,"completionDate":"2027-12-31"},{"nctId":"NCT06118710","phase":"PHASE4","title":"Evaluation of the Omission of Dexamethasone in Premedication Regimens During Paclitaxel Treatment","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2024-06-25","conditions":["Cancer"],"enrollment":500,"completionDate":"2027-08-01"},{"nctId":"NCT06039137","phase":"","title":"The Effect of Switching the H1-antagonist Clemastine to Cetirizine in Premedication Regimens During Paclitaxel Treatment","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2022-06-01","conditions":["Solid Tumor"],"enrollment":395,"completionDate":"2023-10-31"},{"nctId":"NCT06315972","phase":"PHASE2","title":"Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity","status":"NOT_YET_RECRUITING","sponsor":"LMU Klinikum","startDate":"2024-04","conditions":["Schizophrenia"],"enrollment":90,"completionDate":"2028-04"},{"nctId":"NCT03942887","phase":"PHASE3","title":"Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2019-05-03","conditions":["ANCA Associated Vasculitis"],"enrollment":100,"completionDate":"2025-04-01"},{"nctId":"NCT01125761","phase":"PHASE3","title":"Efficacy and Safety of the Association Drugs in Patients With Allergic Dermatitis","status":"WITHDRAWN","sponsor":"Azidus Brasil","startDate":"2010-11","conditions":["Dermatitis"],"enrollment":0,"completionDate":"2010-11"},{"nctId":"NCT05199103","phase":"NA","title":"Antithymocyte Globulin as a Second Line Therapy in Graves Orbitopathy","status":"UNKNOWN","sponsor":"Medical University of Silesia","startDate":"2020-01-01","conditions":["Graves Orbitopathy"],"enrollment":20,"completionDate":"2023-12-31"},{"nctId":"NCT04710810","phase":"PHASE1","title":"UCB Stem Cells for Autism Spectrum Disorders","status":"COMPLETED","sponsor":"St. Petersburg Bekhterev Research Psychoneurological Institute","startDate":"2019-11-04","conditions":["Autism Spectrum Disorder"],"enrollment":30,"completionDate":"2021-07-31"},{"nctId":"NCT01257061","phase":"PHASE3","title":"Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment","status":"COMPLETED","sponsor":"EMS","startDate":"2012-09-06","conditions":["Eczema"],"enrollment":310,"completionDate":"2013-08-02"},{"nctId":"NCT03826004","phase":"NA","title":"Clemastine in Cardiovascular Surgery","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2019-02-20","conditions":["Efficacy and Safety"],"enrollment":100,"completionDate":"2020-01-10"},{"nctId":"NCT00913549","phase":"PHASE1","title":"To Demonstrate the Relative Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets","status":"COMPLETED","sponsor":"Sandoz","startDate":"1989-12","conditions":["Allergy"],"enrollment":36,"completionDate":"1990-01"},{"nctId":"NCT02613091","phase":"PHASE1","title":"Effect of Clemastine Fumarate on Color Vision in Healthy Controls","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-04","conditions":["Healthy Subjects"],"enrollment":23,"completionDate":""},{"nctId":"NCT00481676","phase":"PHASE2","title":"Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-05","conditions":["Chronic Urticaria"],"enrollment":49,"completionDate":"2009-04"},{"nctId":"NCT01239719","phase":"PHASE3","title":"Randomized Study for Effectiveness and Safety Evaluation of Dexamethasone 0.5 mg + Fumarate Clemastine 1 mg Compared to Dexamethasone 0.5 mg in Patients With Allergic Dermatitis","status":"UNKNOWN","sponsor":"Azidus Brasil","startDate":"2011-03","conditions":["Allergy","Dermatitis"],"enrollment":96,"completionDate":"2011-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Syrup, Tablet","formulations":[{"form":"SYRUP","route":"ORAL","productName":"CLEMASTINE FUMARATE"},{"form":"SYRUP","route":"ORAL","productName":"Clemastine Fumarate"},{"form":"TABLET","route":"ORAL","productName":"Clemastine Fumarate"},{"form":"TABLET","route":"Oral","productName":"Clemastine Fumarate"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147773","MMSL":"224","NDDF":"003410","UNII":"95QN29S1ID","VUID":"4019681","CHEBI":"CHEBI:3738","VANDF":"4018759","INN_ID":"2231","RXNORM":"142430","UMLSCUI":"C0008929","chemblId":"CHEMBL1200795","ChEMBL_ID":"CHEMBL1626","KEGG_DRUG":"D00666","DRUGBANK_ID":"DB00283","PUBCHEM_CID":"26987","SNOMEDCT_US":"372744005","IUPHAR_LIGAND_ID":"6063","SECONDARY_CAS_RN":"14976-57-9","MESH_DESCRIPTOR_UI":"D002974"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Novartis","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"37%"},"publicationCount":487,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"D04AA14","allCodes":["D04AA14","R06AA04","R06AA54"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 13","pmid":"41780166","title":"Oligodendrocyte-specificfusdepletion preserves CA1 single-unit fidelity and stabilizes network dynamics during chronic recording.","journal":"Journal of neural engineering"},{"date":"2026 Feb 27","pmid":"41758934","title":"Immune-adaptive pathogen variation reveals targetable mediators of gram-positive bacterial killing in macrophages.","journal":"Science advances"},{"date":"2026 Mar 1","pmid":"41755774","title":"Clemastine Restores Myelination Protein Expression in S16 Schwann Cells by Enhancing AMPK Activation and Reducing H(2)O(2)-Induced Oxidative Stress.","journal":"Biomolecules & therapeutics"},{"date":"2026 Feb 24","pmid":"41719338","title":"Clemastine fumarate promotes myelin repair in a nonhuman primate model of demyelination characterized by absent spontaneous remyelination.","journal":"Proceedings of the National Academy of Sciences of the United States of America"},{"date":"2026 May","pmid":"41690435","title":"Myelin damage in major depressive disorder: Insights from neuroimaging, molecular mechanisms, and therapeutic perspectives.","journal":"Neuroscience and biobehavioral reviews"}],"companionDiagnostics":[],"genericManufacturers":10,"_genericFilersChecked":true,"genericManufacturerList":["Actavis Mid Atlantic","Ani Pharms","Apotex Inc","Genus","L Perrigo Co","New Heightsrx","Omnivium Pharms","Pld Acquisitions Llc","Teva Pharms","Wockhardt Bio Ag"],"status":"approved","companyName":"Novartis","companyId":"","modality":"Small molecule","firstApprovalDate":"1977","aiSummary":"","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1977-02-25T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1994-01-26T00:00:00.000Z","mah":"GENUS","brand_name_local":null,"application_number":"ANDA073283"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1997-05-05T00:00:00.000Z","mah":"GENUS","brand_name_local":null,"application_number":"ANDA073399"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1997-12-17T00:00:00.000Z","mah":"NEW HEIGHTSRX","brand_name_local":null,"application_number":"ANDA074884"},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:26:15.564507+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}